English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Clinical Infectious Diseases 2004; 39:29–30 This article is in the public domain, and no copyright is claimed. 1058-4838/2004/3901-0006 Pertussis is the only disease for which children are routinely vaccinated that is not at historically low levels in the United States. The increases seen in pertussis are not due to ineffective vaccines or programs. The effectiveness of acellular pertussis vaccine has been demonstrated to be high in both prelicensure studies and postlicensure evaluations, and coverage among vaccine-eligible age groups remains high. However, pertussis continues to strike those who are susceptible because of waning vaccine-induced immunity and infants who are too young to have completed the primary vaccination series. To address the issue of waning immunity, formulations of acellular pertussis vaccine combined with diphtheria and tetanus toxoids for adolescents and adults (TdaP) are now under development in the United States; TdaP vaccines are already licensed and available in Canada, Germany, France, and Australia and are expected in the United States soon. Because a vaccine to prevent pertussis in older children, adolescents, and adults is likely to be available soon, how should policy makers approach its use? Our recommendations for use of TdaP should be guided by our knowledge, and there are things we know well about pertussis. Outbreaks of pertussis occur in a variety of settings but are most frequently recognized in middle and high schools. Antimicrobial prophylaxis is recommended for close contacts of patients with pertussis, and outbreak response is a complex, costly, and disruptive activity for schools and local health authorities. The rates of hospitalization, serious complications, and death among adolescents are low, but cough illness due to pertussis is prolonged, and the health impact—in terms of medical visits, antimicrobial treatment, and experience of illness—is significant. Currently, these school-based outbreaks are not preventable, and the only strategies for control are identification, isolation, and prophylaxis of contacts.

Prevention of Pertussis among Adolescents by Vaccination: Taking Action on What We Know and Acknowledging What We Do Not Know